tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Cataract D002386 34 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Cheilitis D002613 2 associated lipids
Cholelithiasis D002769 16 associated lipids
Cholestasis D002779 23 associated lipids
Choline Deficiency D002796 16 associated lipids
Hemophilia B D002836 3 associated lipids
Chronic Disease D002908 7 associated lipids
Cicatrix D002921 9 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Colitis D003092 69 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Collagen Diseases D003095 2 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Confusion D003221 4 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Tanabe K et al. Prospective analysis and successful treatment of thrombotic microangiopathy in renal allografts under tacrolimus immunosuppression. 2001 Nov-Dec Transplant. Proc. pmid:11750571
Claesson K et al. Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients. 1998 Transplant. Proc. pmid:9636524
Marin-Gomez LM et al. Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: observational study. 2009 Jul-Aug Transplant. Proc. pmid:19715867
Peddi VR et al. Tacrolimus eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation. 1998 Transplant. Proc. pmid:9532151
Ortiz de Urbina J et al. Advagraf de novo in liver transplantation: a single-center experience. 2011 Transplant. Proc. pmid:21486583
Pérez MJ et al. Cardiovascular risk factors after liver transplantation: analysis of related factors. 2011 Transplant. Proc. pmid:21486587
Ichikura H et al. Conversion of renal transplant immunosuppression from tacrolimus (FK 506) to cyclosporine: a single center experience. 2000 Transplant. Proc. pmid:11119911
Manu M et al. Impact of tacrolimus on hyperlipidemia after renal transplantation: a Japanese single center experience. 2000 Transplant. Proc. pmid:11119912
Chang HY et al. Long-term follow-up of arrhythmia characteristics and clinical outcomes in heart transplant patients. 2013 Jan-Feb Transplant. Proc. pmid:23375324
Klintmalm GB et al. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679840
Abu-Elmagd KM et al. Strategy of FK 506 therapy in liver transplant patients: effect of graft function. 1991 Transplant. Proc. pmid:1721272
Kusne S et al. Infections during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation. 1992 Transplant. Proc. pmid:1371626
Ye Q et al. Functional analysis of hamster kidney xenografts in the rat: possible functional incompatibility and adaptation of hamster kidney grafts in a xenogenic rat environment. 1996 Transplant. Proc. pmid:8623350
Lee KK et al. Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. 1990 Transplant. Proc. pmid:1689908
Müller H et al. Immunosuppression with generic tacrolimus and mycophenolate mofetil in renal transplant recipients: preliminary report in Chile. 2008 Transplant. Proc. pmid:18454992
Osako M et al. Alloimmune response may be involved in neointimal hyperplasia in cryopreserved aortic allografts. 2001 Transplant. Proc. pmid:11406250
Faivre L et al. FK 506 dose in transplantation: from theory to practice. 2001 Transplant. Proc. pmid:11406256
Mueller AR et al. Does initial graft function influence the outcome after liver transplantation? 1998 Transplant. Proc. pmid:9636594
Lang M et al. Impact of immunosuppression in liver transplantation across a positive crossmatch. 1998 Transplant. Proc. pmid:9636595
Takeuchi H et al. Lymphocyte sensitivity to cyclosporine and tacrolimus in chronic renal failure patients and clinical significance in renal transplantation. 1998 Transplant. Proc. pmid:9474950
Hatori M et al. Clinicopathologic examination of no-episode biopsies in well-functioning renal allografts. 1998 Transplant. Proc. pmid:9474971
de la Fuente S et al. Long-term survivors after pediatric liver transplatation are at increased risk for development of cardiovascular disease events: analysis of 30 cases. 2014 Transplant. Proc. pmid:25420837
Akiyama T et al. Mizoribine in combination therapy with tacrolimus for living donor renal transplantation: analysis of a nationwide study in Japan. 2005 Transplant. Proc. pmid:15848551
Alloway R et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. 2005 Transplant. Proc. pmid:15848559
Sawai T et al. A successful induction of tolerance by perioperative intrathymic injection in rat "high-responder" heart transplantation. 1999 Transplant. Proc. pmid:10578275
Donnelly JG and Soldin SJ Purification of a 50- to 58-kDa immunophilin from human spleen and a Jurkat T-cell line capable of binding cyclosporine A, FK 506, and rapamycin. 1991 Transplant. Proc. pmid:1721305
Morris RE et al. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. 1990 Transplant. Proc. pmid:1697111
Jin KB et al. The production of reactive oxygen species in tacrolimus-treated glial cells. 2008 Transplant. Proc. pmid:18929834
Chuang JP et al. Does immunosuppressive pharmacotherapy affect isoagglutinin titers? 2008 Transplant. Proc. pmid:18929836
Bäckman L et al. Chronic nephrotoxicity of FK 506 after liver transplantation. 1994 Transplant. Proc. pmid:7518159
Bäckman L et al. Whole blood and plasma levels of FK 506 after liver transplantation: correlation with toxicity. 1994 Transplant. Proc. pmid:7518160
Loucaidou M et al. Cytokine polymorphisms do not influence acute rejection in renal transplantation under tacrolimus-based immunosuppression. 2005 Transplant. Proc. pmid:15919456
Yagihashi A et al. Changes in cell surface markers in human small bowel transplantation with FK 506. 1992 Transplant. Proc. pmid:1376522
Sakimoto H et al. Prolonged survival of hamster-to-rat pancreas xenografts by FK 506 and splenectomy. 1995 Transplant. Proc. pmid:7533394
Abu-Elmagd K et al. Management of intestinal transplantation in humans. 1992 Transplant. Proc. pmid:1376523
Celli S et al. Mechanisms of protection from humoral rejection by a xenografted liver. 1995 Transplant. Proc. pmid:7533395
Land W Mycophenolate mofetil-based immunosuppressive therapy: induction, maintenance, and conversion protocols in renal transplantation. 1999 Transplant. Proc. pmid:10616558
Lewis WD et al. FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection. 1991 Transplant. Proc. pmid:1721336
Woodle ES et al. FK 506: reversal of humorally mediated rejection following ABO-incompatible liver transplantation. 1991 Transplant. Proc. pmid:1721337
Jain AK et al. Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients. 2002 Transplant. Proc. pmid:12176474
Metcalfe SM et al. In vitro transcription and translation of the tumour suppressor protein P53: qualitative and quantitative effects of FK506 and rapamycin. 1998 Transplant. Proc. pmid:9865315
Moro JA et al. Randomized prospective study of the evolution of renal function depending on the anticalcineurin used. 2008 Transplant. Proc. pmid:19010143
Barrera-Pulido L et al. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients. 2008 Transplant. Proc. pmid:19010156
Nüssler NC et al. CD8+ host cells infiltrate the intestinal mucosa after allogeneic small bowel transplantation even in the absence of acute rejection. 1996 Transplant. Proc. pmid:8907898
Scantlebury VP et al. Pediatric kidney transplantation at the University of Pittsburgh. 1994 Transplant. Proc. pmid:7509095
Nishi K et al. The colon displays an absorptive capacity of tacrolimus. 2004 Transplant. Proc. pmid:15050160
Todo S et al. Clinical small bowel or small bowel plus liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721369
Hernández D et al. Cardiovascular risk profile in nondiabetic renal transplant patients: cyclosporine versus tacrolimus. 2003 Transplant. Proc. pmid:12962773
Tzakis AG et al. Use of FK 506 in pediatric patients. 1991 Transplant. Proc. pmid:1703353
Pascual J et al. A low incidence of new-onset insulin-dependent diabetes mellitus using tacrolimus in kidney recipients in Europe. 2003 Transplant. Proc. pmid:12962785
Craig AM et al. A cost-effectiveness analysis of tacrolimus versus cyclosporine microemulsion following kidney transplantation. 2002 Transplant. Proc. pmid:12176519
Rashid I et al. Medium-term outcome using sirolimus-tacrolimus combination in adult renal transplant recipients. 2002 Transplant. Proc. pmid:12176520
Takeda M et al. Immunologic factors contributing to acute rejection in lungs xenotransplanted between primates. 1998 Transplant. Proc. pmid:9838670
Murase N et al. Immunomodulation of intestinal transplant with allograft irradiation and simultaneous donor bone marrow infusion. 1999 Feb-Mar Transplant. Proc. pmid:10083238
Fukushima N et al. Prolonged survival of pig cardiac xenografts in baboons by sequential cardiac transplantation. 1998 Transplant. Proc. pmid:9838671
Schulz T et al. Mycophenolate mofetil/prednisolone/single-shot ATG with tacrolimus or cyclosporine in pancreas/kidney transplantation: first results of an ongoing prospective randomized trial. 1999 Feb-Mar Transplant. Proc. pmid:10083251
Krzyżowska K et al. No Significant Influence of Reduced Initial Tacrolimus Dose on Risk of Underdosing and Early Graft Function in Older and Overweight Kidney Transplant Recipients. Transplant. Proc. pmid:30056895
Sharma A et al. Incidence of glucose metabolic abnormalities in Indian living renal allograft recipients on tacrolimus-based triple drug immunosuppression. 2008 Transplant. Proc. pmid:18790252
Gassel HJ et al. Selective immunosuppression induces tolerance after liver transplantation: an immunohistochemical and cytofluorographic analysis of the graft and recipient immune system. 1997 Feb-Mar Transplant. Proc. pmid:9123253
Kim K et al. Everolimus-Induced Systemic Serositis After Simultaneous Liver and Kidney Transplantation: A Case Report. Transplant. Proc. pmid:28104132
Burke GW et al. Donor bone marrow infusion in simultaneous pancreas/kidney transplantation with OKT3 induction: evidence for augmentation of chimerism. 1997 Feb-Mar Transplant. Proc. pmid:9123275
Kliem V et al. FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis. 1996 Transplant. Proc. pmid:8962227
Becker G et al. Tacrolimus (FK 506) therapy in simultaneous pancreas kidney transplantation. 1996 Transplant. Proc. pmid:8962228
Ito A et al. Induction of tolerance in rat cardiac allograft model by intrathymic injection of donor bone marrow cells. 1995 Transplant. Proc. pmid:7536974
Büttemeyer R et al. Peripheral nerve allotransplant immunosuppressed with FK 506: preliminary results. 1995 Transplant. Proc. pmid:7536979
Muirhead N et al. A comparison between cyclosporine and tacrolimus-based immunosuppression for renal allografts: renal function and blood pressure after 5 years. 2003 Transplant. Proc. pmid:14611965
Lopez OL et al. Neuropathologic findings in liver transplantation: a comparative study of cyclosporine and FK 506. 1991 Transplant. Proc. pmid:1721400
Takaya S et al. Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506. 1993 Transplant. Proc. pmid:7685953
Ali IH et al. Incidence and risk factors for post-renal transplant diabetes mellitus. 2011 Transplant. Proc. pmid:21440763
Yasunami Y et al. Effects of a novel immunosuppressive agent, FK-506, on islet allograft survival in the rat. 1989 Transplant. Proc. pmid:2468234
Tsai SF et al. Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database. 2012 Transplant. Proc. pmid:22310612
Fellermann K et al. Tacrolimus: a new immunosuppressant for steroid refractory inflammatory bowel disease. 2001 Transplant. Proc. pmid:11377517
Suwelack B et al. Replacement of calcineurin inhibitors by mycophenolate mofetil: effect on hemoglobine levels. 2002 Transplant. Proc. pmid:12176585
Orsenigo R et al. FK506 and SMS 201-995: effect on heterotopic heart transplantation in rats. 2001 Feb-Mar Transplant. Proc. pmid:11266956
Mendes J et al. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients. 2009 Transplant. Proc. pmid:19376366
McMaster P et al. Liver transplantation: changing goals in immunosuppression. 1998 Transplant. Proc. pmid:9723295
Weir MR Optimizing early de novo immunosuppression with sirolimus. 2008 Transplant. Proc. pmid:19100903
Dedhia P et al. Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report. Transplant. Proc. pmid:28104134
Gotoh M et al. Tolerance induction by liver grafting and FK 506 treatment in nonhuman primates. 1991 Transplant. Proc. pmid:1721431
Ishikawa M et al. Acetaminophen absorption test as a useful indicator of small intestinal rejection in rats. 1996 Transplant. Proc. pmid:8658911
Valdivia LA et al. Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721432
Sanghvi A et al. FK-506 enhances cyclosporine uptake by peripheral blood lymphocytes. 1987 Transplant. Proc. pmid:2445074
Ochiai T et al. Prolongation of canine renal allograft survival by treatment with FK-506. 1987 Transplant. Proc. pmid:2445075
Sindhi R et al. Preliminary immunosuppression withdrawal strategies with sirolimus in children with liver transplants. 2002 Transplant. Proc. pmid:12176651
Zajicek A et al. Thirteen years' experience in pediatric liver transplantation: differences between tacrolimus and cyclosporine. 2002 Transplant. Proc. pmid:12176653
Peltekian K et al. De novo use of low-dose tacrolimus and sirolimus in liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267318
Gómez G et al. Acute tacrolimus nephrotoxicity in renal transplant patients treated with clarithromycin. 1999 Transplant. Proc. pmid:10500563
Khoury N et al. Posttransplant diabetes mellitus in kidney transplant recipients under tacrolimus immunosuppression. 2000 Transplant. Proc. pmid:11134791
Pretagostini R et al. Delayed Introduction of Everolimus in De Novo Renal Transplanted Patients: A Single-Center Experience. 2016 Transplant. Proc. pmid:27109947
Dall'Agnol DJ et al. Effects of immunosuppressive drugs on gastrointestinal transit of rats: effects of tacrolimus, cyclosporine, and prednisone. Transplant. Proc. pmid:25131057
Nossal GJ Summary of the First International FK 506 Congress: perspectives and prospects. 1991 Transplant. Proc. pmid:1721464
Barten MJ et al. Assessment of immunosuppression by lymphocyte functions in human blood. 2002 Transplant. Proc. pmid:12431640
Reimer J et al. Quality of life after kidney transplantation--the impact of tacrolimus. 2001 Feb-Mar Transplant. Proc. pmid:11267573
Fritsche L et al. Conversion to mycophenolate mofetil for chronic progressive deterioration of renal allograft function: first clinical experiences in 44 patients. 1998 Transplant. Proc. pmid:9636481
Miura S et al. Effect of tacrolimus on the outcome of renal transplantation with donor-specific blood transfusion. 1998 Transplant. Proc. pmid:9636492
van Hooff JP et al. Preservation of renal function and cardiovascular risk factors. 2006 Transplant. Proc. pmid:16979974
Girman P et al. Similar early complication rate in simultaneous pancreas and kidney recipients on tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus immunosuppressive regimens. 2010 Jul-Aug Transplant. Proc. pmid:20692391
Montero EF et al. Gangliosides on intestinal microcirculation and animal survival during reperfusion. 2004 Transplant. Proc. pmid:15194293
Goto S et al. Effect of FK 506 and cyclosporine on heart allograft survival in rats. 1991 Transplant. Proc. pmid:1703700
Flavin T et al. Initial experience with FK 506 as an immunosuppressant for nonhuman primate recipients of cardiac allografts. 1991 Transplant. Proc. pmid:1703701